Nanobiotix spins out Curadigm
Cancer-focussed Nanobiotix SA has spun out Curadigm, which offers a platform to improve the bioavailability of nanomedicines by reducing liver and spleen toxicity and accumulation.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1118 entries already.
Entries by Thomas Gabrielczyk
Most expensive gene therapy globally approved
/in News/by Thomas GabrielczykThe FDA has approved Novartis-subsidiary AveXis Inc’s spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec-xioi). The company wants to set the price tag at $2,125m per dose.
Chiesi acquires ex-US Raxone marketing rights
/in News/by Thomas GabrielczykChiesi Farmaceutici has licenced commercialiation rights for LHON treatment Raxone (idebenone) from Santhera Pharmaceuticals for CHF50m (44m) in cash plus sales milestones.
Evotec acquires CDMO Just Biotherapeutics in US$90m deal
/in News/by Thomas GabrielczykEvotec SE is set to acquire biologics manufacturing specialist Just Biotherapeutics, Inc in a deal that could amount up to $90m.
AI improves protein manufacture
/in News/by Thomas GabrielczykResearchers at German regulatory authority Paul-Ehrlich Institute (PEI) have patented a method to accurately forecast biotech-based protein synthesis in host cells.
DNA Script raises US$38.5m in Series B round
/in News/by Thomas GabrielczykIn an oversubscribed Series B round led by LSP, Paris-based DNA Script raised US$38.5. Bpifrance and existing investors Illumina Ventures, M. Ventures, Sofinnova Partners, Kurma Partners and Idinvest Partners contributed.
Dutch-Italian team improves retinal gene therapy
/in News/by Thomas GabrielczykResearchers from Universities Nijmegen and Naples have presented a retinal AAV-based gene therapy delivery system that can express huge genetic elements by assembling protein fragments from several vectors.
Mobidiag secures 25m loan from EIB
/in News/by Thomas GabrielczykMolecular diagnostics company Mobidiag has received an EIB loan to accelerate the development and commercialisation of its in vitro diagnostic solutions for infectious diseases.
Philogen SpA raises 62m to push registration
/in News/by Thomas GabrielczykPrivately financed Italian antibody-cytokine fusion protein specialist Philogen SpA has secured 62m from private investors including the Neri and Dompé families to push registration of two wholly owned Phase III […]
Halt of Polyphor trial shrinks company valuation
/in News/by Thomas GabrielczykRoche had a nose for success when the pharma giant ended the CHF500m deal with Polyphor in November 2015. Now, the antibiotics maker stopped a Phase III trial of its […]